Free Trial

Bavarian Nordic A/S Q1 2023 Earnings Report

Bavarian Nordic A/S logo
$8.96 +0.12 (+1.36%)
(As of 12/20/2024 05:55 PM ET)

Bavarian Nordic A/S EPS Results

Actual EPS
$0.25
Consensus EPS
$0.09
Beat/Miss
Beat by +$0.16
One Year Ago EPS
N/A

Bavarian Nordic A/S Revenue Results

Actual Revenue
$180.47 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Bavarian Nordic A/S Announcement Details

Quarter
Q1 2023
Time
N/A

Conference Call Resources

The #1 Coin for November 2024 (Ad)

Grayscale Investments just announced a new fund offering access to a HOT new DeFi coin… And thanks to this newly established trust, I believe this coin could skyrocket up to 150x+ in the next 30 days alone! I've compiled everything you need to know about this once-in-a-lifetime DeFi project into a brand-new comprehensive guide…

You can get access to the report by clicking here now…

Bavarian Nordic A/S Earnings Headlines

The #1 Coin for November 2024
Grayscale Investments just announced a new fund offering access to a HOT new DeFi coin… And thanks to this newly established trust, I believe this coin could skyrocket up to 150x+ in the next 30 days alone! I've compiled everything you need to know about this once-in-a-lifetime DeFi project into a brand-new comprehensive guide…
See More Bavarian Nordic A/S Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Bavarian Nordic A/S? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Bavarian Nordic A/S and other key companies, straight to your email.

About Bavarian Nordic A/S

Bavarian Nordic A/S (OTCMKTS:BVNRY) is a fully-integrated biotechnology company focused on vaccination technology. The company’s work is built around two primary platforms that provide numerous benefits to the health industry and individuals. The company’s primary technology is MVA-BN which stands for Modified Vaccine Ankara-Bavarian Nordic. This vaccination platform is a non-replicating platform, meaning that live-virus vaccines cannot reproduce and spread within the host. This is central to the platform's high tolerance rate. MVA-BN is approved as a smallpox and monkeypox vaccine in the US, Canada, and the EU. It is also included in the US Strategic National Stockpile and is being used worldwide to control the 2022 Monkeypox outbreak.

Bavarian Nordic is headquartered in Hellerup, Denmark with manufacturing sites in Denmark and Germany. The company maintains offices in Switzerland, the UK, Japan, and North Carolina in the United States. The company was incorporated in 1992 and had 4 approved products under 7 brand names available for use. Its MVA-BN non-replicating smallpox and monkeypox vaccines are available under the IMVAMUNE, IMVANEX and JYNNEOS names.

The company’s second platform is the Vaccinia-Fowlpox-TRICOM platform for treating cancers. The platform can be targeted to attack specific markers found in numerous cancers. The company’s other marketable vaccines are Rabipur for rabies, MVABEA for Ebola and Marburg Hemorrhagic fever, and Encepur for tick-borne encephalitis.

The company’s pipeline has 4 potential candidates for the market. These include a freeze-dried version of MVA-BN for smallpox, MVA-BN for RSV (respiratory infection), and TAEK-VAC for certain cancers. The company’s COVID-19/SARS vaccine boosters have shown effectiveness 6 months after dosing. 
View Bavarian Nordic A/S Profile

More Earnings Resources from MarketBeat

Upcoming Earnings